Zimmer Launches Single Injection Pain Relief Solution at the 2013 AAOS Annual Meeting

Zimmer Launches Single Injection Pain Relief Solution at the 2013 AAOS Annual
                                   Meeting

Gel-One® Offers Knee Arthritis Sufferers Pain Relief and Restored Mobility in
a Single Injection

PR Newswire

CHICAGO, March 20, 2013

CHICAGO, March 20, 2013 /PRNewswire/ -- Zimmer Holdings, Inc. (NYSE: ZMH; SIX:
ZMH), a global leader in musculoskeletal health, today introduced Gel-One®
Cross-linked Hyaluronate  at the 2013 American Academy of Orthopaedic Surgeons
Annual Meeting. Gel-One Hyaluronate  is an injectable gel approved for the
treatment of osteoarthritis of the knee. The product is the first low-volume
viscosupplement designed to provide pain relief and improve knee joint
function through a single-injection treatment.

"Zimmer is committed to meeting osteoarthritis patients at every stage of the
continuum of care, and this innovative cushioning gel offers therapy with the
simplicity of a single, in-office injection," said David Nolan, Zimmer Senior
Vice President. "Gel-One Hyaluronate is a supplement to natural synovial
fluid, offering pain relief to patients living with knee osteoarthritis. We
are excited to introduce this joint preservation technology to surgeons and
their patients in the United States."

Gel-One Hyaluronate is indicated for the treatment of pain in knee
osteoarthritis patients who have failed to respond to non-pharmacologic
therapy, non-steroidal anti-inflammatory drugs (NSAIDs), or simple analgesics
such as acetaminophen. Unlike other viscosupplement treatments, highly
purified Gel-One Hyaluronate  requires only 3mL for safe and effective
treatment. Gel-One Hyaluronate  is manufactured using a unique cross-linking
process that enables increased viscoelasticity. 

In a clinical study, Gel-One Hyaluronate  demonstrated  statistically
significant pain relief over a Phosphate Buffered Saline control (PBS).
Patients receiving Gel-One Hyaluronate experienced, on average, a nearly 40
percent reduction in pain from baseline (28 mm reduction in WOMAC pain on a
100 mm VAS, Visual Analog Scale).

For more information about Gel-One Hyaluronate, visit Zimmer at Booth 529 at
the 2013 American Academy of Orthopaedic Surgeons annual meeting in Chicago,
or go to www.zimmer.com. 

Gel-One® is a registered trademark of Seikagaku Corporation.

About the Company
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs,
develops, manufactures and markets orthopaedic reconstructive, spinal and
trauma devices, dental implants, and related surgical products. Zimmer has
operations in more than 25 countries around the world and sells products in
more than 100 countries. Zimmer's 2012 sales were approximately $4.5
billion. The Company is supported by the efforts of more than 8,500 employees
worldwide.

Zimmer Safe Harbor Statement
This press release contains forward-looking statements within the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995 based on
current expectations, estimates, forecasts and projections about the
orthopaedics industry, management's beliefs and assumptions made by
management. Forward-looking statements may be identified by the use of
forward-looking terms such as "may," "will," "expects," "believes,"
"anticipates," "plans," "estimates," "projects," "assumes," "guides,"
"targets," "forecasts," and "seeks" or the negative of such terms or other
variations on such terms or comparable terminology. These statements are not
guarantees of future performance and involve risks, uncertainties and
assumptions that could cause actual outcomes and results to differ
materially. For a list and description of such risks and uncertainties, see
our periodic reports filed with the U.S. Securities and Exchange Commission.
We disclaim any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise, except as may be set forth in our periodic reports.
Readers of this document are cautioned not to place undue reliance on these
forward-looking statements, since, while we believe the assumptions on which
the forward-looking statements are based are reasonable, there can be no
assurance that these forward-looking statements will prove to be accurate.
This cautionary statement is applicable to all forward-looking statements
contained in this document.



SOURCE Zimmer Holdings, Inc.

Website: http://www.zimmer.com
Contact: Garry Clark, +1-574-372-4493, garry.clark@zimmer.com
 
Press spacebar to pause and continue. Press esc to stop.